Bank of America’s Zevra Therapeutics ZVRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $604K | Sell |
64,837
-81,527
| -56% | -$735K | ﹤0.01% | 4798 |
|
|
2025
Q4 | $1.31M | Sell |
146,364
-141,681
| -49% | -$1.34M | ﹤0.01% | 4359 |
|
|
2025
Q3 | $2.74M | Buy |
288,045
+64,193
| +29% | +$644K | ﹤0.01% | 4541 |
|
|
2025
Q2 | $1.97M | Buy |
223,852
+134,437
| +150% | +$1.09M | ﹤0.01% | 4786 |
|
|
2025
Q1 | $670K | Sell |
89,415
-8,830
| -9% | -$70.2K | ﹤0.01% | 5494 |
|
|
2024
Q4 | $819K | Buy |
98,245
+67,772
| +222% | +$578K | ﹤0.01% | 5197 |
|
|
2024
Q3 | $211K | Buy |
30,473
+2,581
| +9% | +$17.5K | ﹤0.01% | 5975 |
|
|
2024
Q2 | $137K | Buy |
27,892
+7,132
| +34% | +$33.8K | ﹤0.01% | 6091 |
|
|
2024
Q1 | $120K | Sell |
20,760
-21,162
| -50% | -$130K | ﹤0.01% | 6150 |
|
|
2023
Q4 | $275K | Buy |
41,922
+1,534
| +4% | +$7.17K | ﹤0.01% | 5889 |
|
|
2023
Q3 | $195K | Buy |
40,388
+17,491
| +76% | +$87.3K | ﹤0.01% | 5919 |
|
|
2023
Q2 | $117K | Buy |
22,897
+16,672
| +268% | +$89.9K | ﹤0.01% | 6133 |
|
|
2023
Q1 | $34.2K | Buy |
6,225
+3,483
| +127% | +$18.4K | ﹤0.01% | 6608 |
|
|
2022
Q4 | $12.6K | Buy |
2,742
+714
| +35% | +$3.63K | ﹤0.01% | 6866 |
|
|
2022
Q3 | $13K | Buy |
2,028
+1,923
| +1,831% | +$10.9K | ﹤0.01% | 7172 |
|
|
2022
Q2 | $0 | Sell |
105
-144,969
| -100% | -$661K | ﹤0.01% | 8452 |
|
|
2022
Q1 | $730K | Buy |
145,074
+112,161
| +341% | +$714K | ﹤0.01% | 5517 |
|
|
2021
Q4 | $286K | Sell |
32,913
-27,974
| -46% | -$250K | ﹤0.01% | 6276 |
|
|
2021
Q3 | $568K | Buy |
60,887
+47,937
| +370% | +$483K | ﹤0.01% | 5550 |
|
|
2021
Q2 | $166K | Buy |
+12,950
| New | +$139K | ﹤0.01% | 6217 |
|
|
2019
Q4 | – | Sell |
-445
| Closed | -$5K | – | 7459 |
|
|
2019
Q3 | $5K | Buy |
+445
| New | +$8.04K | ﹤0.01% | 6859 |
|
|
2019
Q2 | – | Sell |
-64
| Closed | -$2K | – | 7449 |
|
|
2019
Q1 | $2K | Buy |
+64
| New | +$2.35K | ﹤0.01% | 6922 |
|
|
2018
Q4 | – | Sell |
-10
| Closed | -$1K | – | 7421 |
|
|
2018
Q3 | $1K | Buy |
+10
| New | +$781 | ﹤0.01% | 7159 |
|
|
2017
Q1 | – | Sell |
-47
| Closed | -$2K | – | 7280 |
|
|
2016
Q4 | $2K | Buy |
47
+46
| +4,600% | +$2.82K | ﹤0.01% | 6857 |
|
|
2016
Q3 | $0 | Sell |
1
-89
| -99% | -$6.33K | ﹤0.01% | 7399 |
|
|
2016
Q2 | $6K | Buy |
+90
| New | +$14.8K | ﹤0.01% | 6637 |
|
|
2016
Q1 | – | Sell |
-151
| Closed | -$48K | – | 7371 |
|
|
2015
Q4 | $48K | Buy |
+151
| New | +$41K | ﹤0.01% | 6059 |
|
Other funds holding ZVRA
WP
NCM
VCM
ACM
Bank of America's ZVRA Position: Q1 2026 in Review
Bank of America reduced its Zevra Therapeutics (ZVRA) stake by 56% in Q1 2026, selling an estimated $735K and leaving 64,837 shares worth $604K. The position accounts for ﹤0.01% of the portfolio, ranked #4798.
Bank of America first reported a position in ZVRA in Q4 2015 and has held it in 27 quarters since. The position peaked at $2.74M in Q3 2025. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.
- Bank of America held 64,837 shares of Zevra Therapeutics worth $604K as of Q1 2026.
- Bank of America sold 81,527 Zevra Therapeutics shares in Q1 2026, an estimated $735K.
- Zevra Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #4798 holding.
- Bank of America first reported a position in Zevra Therapeutics in Q4 2015 and has held it in 27 quarters since.
- Bank of America's Zevra Therapeutics position peaked at $2.74M in Q3 2025.
- 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.